Inc., a privately held specialty biopharmaceutical company, announced today
that it had acquired certain assets from DelSite (formerly Carrington Laboratories,
Inc.) out of Chapter 7 bankruptcy proceedings in the U.S. Bankruptcy Court for
the Northern District of Texas, Dallas Division.
Before the bankruptcy, DelSite was headquartered in Irving Texas, and had manufacturing
facilities in Irving and Costa Rica and a research lab in College Station, Texas.
The DelSite assets acquired include the patented, naturally derived, biocompatible,
resorbable biopolymer GelSite®, the GelVacTM nasal powder platform technology,
lab equipment, intellectual property, and other related products. The GelSite®
polymer has been tested in various vaccine formulations for administration by
the nasal route and injection.
Nanotherapeutics also acquired the in-situ gelling nasal powder influenza vaccine
Phase I clinical program based on the novel GelVacTM powder formulation that
incorporates the GelSite® polymer. GelSite® provides mucoadhesion and
sustained antigen release within the nasal cavity for enhancement of the immune
response. This vaccine possesses distinct potential advantages, including induction
of both mucosal and systemic immunity, room temperature stability, prolonged
shelf life, cold-chain-free distribution, and needle-free administration that
can be particularly valuable in meeting the needs for pandemic preparation and
Dr. James Talton, President and CEO of Nanotherapeutics stated that the Company
intended to reactivate the Phase 1 clinical program (“Double Blind, Randomized,
Placebo Controlled Dose Escalation Study to Assess Safety and Immunogenicity
of an Inactivated H5N1 Influenza Vaccine Administered in GelVacTM Nasal Powder
to Healthy Young Adults”) in the near future. Nanotherapeutics has retained
Dr. Yawei Ni, former Chief Scientific Officer, to assist in the transfer of
DelSite’s research and clinical programs to Nanotherapeutics.